• 1
    Mease P. TNFα therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004; 63: 7558.
  • 2
    Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005; 64 Suppl 2: 8790.
  • 3
    Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004; 140: 4046.
  • 4
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 23945.
  • 5
    Padial MA, Alvarez-Ferreira J, Tapia B, Blanco R, Manas C, Blanca M, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol 2004; 150: 13942.
  • 6
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2: 147.
  • 7
    Verea MM, del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 547.
  • 8
    Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004; 3: 43940.
  • 9
    Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004; 50: 16902.
  • 10
    Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions induced by antitumour necrosis factor-α treatment: two cases. Br J Dermatol 2004; 150: 5067.
  • 11
    Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 82934.
  • 12
    Kary S, Worm M, Fritz J, Audring H, Scherer HU, Lee HH, et al. New onset or aggravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNFα antagonists: report of eight cases [abstract]. European League Against Rheumatism: Annual European Congress of Rheumatology, Berlin, Germany, June 9–12, 2004. Abstract no. FRI0095. URL:
  • 13
    Haibel H, Rudwaleit M, Strasser C, Spiller I, Dorner T, Sieper J. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNFα-blocking agents: four case reports [abstract]. European League Against Rheumatism: Annual European Congress of Rheumatology, Berlin, Germany, June 9–12, 2004. Abstract no. SAT0061. URL:
  • 14
    Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003; 15: 3806.
  • 15
    Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med 1991; 174: 14616.
  • 16
    Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398405.
  • 17
    Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors. Rheumatology (Oxford) 2005; 44: 1725.
  • 18
    Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin αEβ7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001; 81: 33547.
  • 19
    The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 2001; 137: 144754.